HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced it has executed definitive agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), in New York, NY, to commercialize electrocardiographic AI algorithms and assets, as well as a memorandum of understanding for on-going cooperation, collaboration and de-identified data access.

Icahn Mount Sinai has invested in the curation of tens of millions of ECG records, enabling its leading researchers to develop a range of disease detection algorithms and state-of-the-art AI foundational methods for use with ECG waveforms. HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai's AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.

"We are thrilled to announce this agreement with Icahn Mount Sinai and look forward to working with one of the top-ranked hospitals for cardiology in the world, at the cutting edge of AI-powered ECG development," said Andrew Simpson, CEO of HeartSciences. "This is a transformative event for the Company and will significantly strengthen our business, accelerate our development and broaden the range of prospective solutions that we will provide for patients. In addition to providing algorithms on our MyoVista device we also intend to develop a cloud-based, device agnostic platform to enable HeartSciences to provide AI-solutions to help identify cardiovascular disease in any care setting worldwide."

"Cardiovascular disease is the leading cause of death around the world, with over 20 million fatalities annually. Accordingly, early detection and treatment are of paramount importance. AI-powered ECG analysis offers the potential of achieving these goals, potentially reducing healthcare costs and improving patient quality of life. Icahn Mount Sinai is a leader in this developing field... We are delighted to enter into this agreement with HeartSciences and look forward to a close relationship and bringing these important technologies to market," said Girish Nadkarni, MD, MPH, System Chair of the Division of Data-Driven and Digital Medicine at the Icahn School of Medicine at Mount Sinai.

"HeartSciences is one of a small number of companies working to bring new AI-powered ECG capabilities to market. We believe that these types of technologies may enable the early detection of heart disease and improve the lives of patients," said Erik Lium, PhD, Chief Commercial Innovation Officer of the Mount Sinai Health System and President of Mount Sinai Innovation Partners.